Seminars in Oncology
Volume 30, Issue 2 , Pages 127-131 , April 2003

Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

References 

  1. Waldenstrom J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia—A new syndrome?. Acta Med Scand. 1944;117:217–247
  2. Dimopoulos MA, O'Brien S, Kantarjian H, et al.  Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leukemia Lymphoma. 1993;11:105–108
  3. Weber D, Dimopoulos MA, Rankin K, et al.  A decade of experience: Primary treatment of Waldenstrom's macroglobulinemia (WM) with 2-chlorodeoxyadenosine (2-CdA) alone or in combination. Blood. 2001;98(suppl 1):2660; abstr)
  4. Hellmann A, Lewandowski K, Zaucha JM, et al.  Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol. 1999;63:35–41
  5. Owen RG, Treon SP, Al-Katib A, et al.  Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110–115
  6. Blade J. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115–1123
  7. Cheson BD, Horning SJ, Coiffier B, et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244–1253
  8. Cheson BD, Bennet JM, Grever M, et al.  National Cancer Institute-sponsored Working Group for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
  9. Alexanian R, Weber D, Liu F. Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med. 1999;123:108–113
  10. Keren DF, Alexanian R, Goeken JA, et al.  Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med. 1999;123:106–107
  11. Dimopoulos MA, Alexanian RA. Waldenstrom's macroglobulinemia. Blood. 1994;83:1452–1459
  12. Kyle R, Treon SP, Alexanian R, et al.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:116–120

☆ Address reprint requests to Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute, Harvard Medical School, LG100, 44 Binney St, Boston, MA 02115. Email: wmp@dfci.harvard.edu.

☆☆ 0093-7754/03/3002-0001$30.00/0

PII: S0093-7754(03)70062-1

doi: 10.1053/sonc.2003.50037

Seminars in Oncology
Volume 30, Issue 2 , Pages 127-131 , April 2003

Article Tools